Background {#Sec1}
==========

MT5-MMP belongs to the multigenic family of Zn^2+^ MMPs, which have been extensively associated with different physiological and pathological settings \[[@CR1], [@CR2]\]. MT5-MMP was first isolated from mouse brain tissue and from glioblastoma by two laboratories in 1999 \[[@CR3], [@CR4]\]. MT5-MMP is predominantly expressed in the nervous system \[[@CR5]\], mainly in neurons, and to a lesser extent also in astrocytes and microglial and endothelial cells \[[@CR6]--[@CR8]\]. MT5-MMP is a 645 amino acid transmembrane glycosylated proteinase that is intracellularly activated by the Ca^2+^-dependent proprotein convertase furin. The latter can also cleave MT5-MMP above its transmembrane domain before it reaches the plasma membrane, thus leading to the release of a truncated active soluble form of MT5-MMP \[[@CR9]\]. MT5-MMP harbors nuclear localization sequences that may tag the proteinase for import into the nucleus \[[@CR10]\]. The proteolytic activity of MT5-MMP is mainly under the control of the endogenous tissue inhibitor of MMP-2 (TIMP-2). Alternatively, adaptor proteins such as Mint-3 regulate MT5-MMP activity by controling its recycling from the trans-golgi network to the cell membrane and its localization in cells \[[@CR11]\]. Moreover, MT5-MMP can be targeted to synapses through interaction with proteins containing PDZ domains such as the AMPA receptor binding protein (ABP) and the glutamate receptor interacting protein (GRIP) \[[@CR12]\]. Overall, MT5-MMP appears as a functionally versatile molecule by virtue of its multiple interactions and localizations in the intracellular and pericellular compartments. An open question is whether MT5-MMP may in turn influence the subcellular localization and activity of its interacting proteins, and should be considered as a "moonlighting protein." One recent example among MMPs concerns MMP-12, which besides its well-known proteolytic activity has also transcription factor properties \[[@CR13]\].Fig. 1Scheme summarizing some known and some hypothetical functions of MT5-MMP in nervous system pathophysiology. *Solid lines/frames* represent biological actions and functional interactions reported in the literature. *Dotted lines/insets* represent the alternative/complementary hypotheses we propose herein. APP: amyloid precursor protein; ABP: AMPA receptor binding protein; CNS: central nervous system; GRIP: glutamate receptor interacting protein; IL-1β: interleukin-1 beta; PNS: peripheral nervous system; TNF-α: tumor necrosis factor-alpha

We are just starting to understand the functional diversity of MT5-MMP in pathology. Early studies showed the ability of MT5-MMP to proteolytically activate MMP-2 \[[@CR3]\] and to process KiSS-1 protein and KISS-1-derived decapeptide metastin \[[@CR14]\], which overall promotes cancer progression. MT5-MMP has been also reported to stimulate neuropathic pain by promoting aberrant axonal sprouting in the spinal cord after sciatic nerve injury in mice \[[@CR15]\]. Moreover, it has been suggested that MT5-MMP is necessary for the inflammatory response to interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) in the peripheral nervous system \[[@CR16]\]. It is noteworthy that no overt developmental abnormalities have been detected in MT5-MMP^−/−^ mice, in contrast with the clearly marked phenotypes they display in pathological conditions \[[@CR15]--[@CR17]\], and also in contrast with other members of the MT-MMP family such as MT1-MMP. This could imply that modulating MT5-MMP activity in pathology may have limited impact on physiology and highlights the therapeutic potential of targeting MT5-MMP.

MT5-MMP in Alzheimer's disease {#Sec2}
==============================

MT5-MMP was first related to AD in a study showing the expression of the proteinase in dystrophic neurites around senile plaques in post-mortem AD brains \[[@CR18]\]. The ability of MT5-MMP to process APP into different truncated APP fragments was later demonstrated \[[@CR19]\]. More recently, two teams, including ours, reported the possible implication of MT5-MMP in AD by means of its functional interaction with APP \[[@CR17], [@CR20]\]. Willem and collaborators showed that MT5-MMP cleavage of APP upstream of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1), combined with cleavage by the α-secretase ADAM-10, generates a so-called Aη-α fragment, which inhibits long-term potentiation (LTP) in vitro \[[@CR20]\]. In parallel, we provided in vivo evidence that MT5-MMP deficiency is associated with a robust and durable amelioration of the pathological outcome in the 5xFAD transgenic mouse model of AD. Compared to 5xFAD mice, bigenic 5xFAD/MT5-MMP^−/−^ exhibited strong decreases of amyloid beta peptide (Aβ) load, gliosis and IL-1β levels, and a better preservation of the neuronal network. Moreover, cognitive and LTP dysfunctions were prevented in bigenic mice \[[@CR17]\]. In the same study, we demonstrated that MT5-MMP interacts with APP and stimulates the formation of Aβ and the toxic C99 APP fragment. Together, these results unveil the contribution of MT5-MMP to AD pathogenesis and strongly suggest its involvement at least in APP processing. However, two complementary non-exclusive mechanistic hypotheses may be put forward on the pathogenic effects of MT5-MMP in AD:

Hypotheses {#Sec3}
==========

The pro-amyloidogenic features of MT5-MMP could result from interactions with APP, which would stimulate its trafficking into endosomes, not necessarily in a proteolytic-dependent manner. These organelles are considered to be the main loci of Aβ production \[[@CR21]\]. Testing this hypothesis would require to modulate the activity/presence of MT5-MMP by gain/loss of function in a cellular system and determine by imaging and biochemical approaches how this might change the distribution of APP and/or Aβ species in the endosomal/lysosomal compartments.The pathogenic role of MT5-MMP in AD could also result from its contribution to the chronic neuroinflammatory process that aggravates AD pathogenesis. Reduced glial reactivity and IL-1β levels found in our bigenic 5xFAD/MT5-MMP^−/−^ mice \[[@CR17]\] could simply result from MT5-MMP deficiency and consequent reduced Aβ load, but we cannot exclude that MT5-MMP inhibition could actually reduce neuroinflammation in an amyloid-independent manner. This idea is consistent with the two following findings: (a) intraplantar injections of IL-1β or TNF-α in MT5-MMP^−/−^ mice do not induce the pro-inflammatory response commonly observed in wild-type mice \[[@CR16]\]. The underlying mechanism involves a deficient processing of N-cadherin, which is a substrate of MT5-MMP, and this appears to alter the communication between mast cells and peripheral sensory neurons. (b) The combined proteolytic action of MT5-MMP and α-secretase on APP can release under certain conditions a N-terminally elongated Aβ form, the neurotoxic Aη-α peptide \[[@CR20]\]. Aη-α generation could have a neuroinflammatory effect associated with its neurotoxicity, but also a consubstantial reduction of the pool of soluble APP-α (sAPPα) generated by the solely action of α-secretase, and reported to be neuroprotective \[[@CR22]\]. Whether MT5-MMP exerts pro-inflammatory activity in the brain could be tested by challenging neural cell cultures deficient for MT5-MMP with pro-inflammatory agents and determine whether well-known responsive genes are transcriptionally activated. Alternatively, the same experimental readout could be used after icv administration of the cytokines of interest in MT5-MMP^−/−^ brains. This idea could be further tested in young bigenic 5xFAD/MT5-MMP^−/−^ mice before Aβ accumulation.

Implications of the hypotheses {#Sec4}
==============================

The confirmation of the first hypothesis will uncover MT5-MMP as a multifunctional enzyme with proteolytic and non-proteolytic features, which could both ultimately stimulate APP metabolism and amyloidogenesis. The confirmation of the second hypothesis would add MT5-MMP to the list of MMPs that promote inflammation in the central nervous system and most interestingly would indirectly support the idea that neuroinflammation is a triggering event of the pathogenic process in AD. Confirming both hypotheses should place MT5-MMP at the crossroads of amyloidogenesis and neuroinflammation, thus providing ground for a better comprehension of AD pathophysiology (see Fig. [1](#Fig1){ref-type="fig"}). In turn, such confirmation would pave the way for the development of innovative therapeutic strategies based on the modulation of MT5-MMP, which should take into account the diversity of its biological actions.
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